Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2013 | 1 |
2014 | 1 |
2020 | 1 |
2021 | 1 |
2023 | 1 |
2024 | 1 |
Search Results
4 results
Results by year
Filters applied: . Clear all
The following terms were ignored: %, %, %
The following terms were not found in PubMed: 20LJ, 5BAuthor
Page 1
Prostate-Specific Antigen Response to Androgen Deprivation Therapy in the Neoadjuvant Setting for High-Risk Prostate Adenocarcinoma (PIRANHA): Pooled Analysis of Two Randomized Clinical Trials.
Int J Radiat Oncol Biol Phys. 2023 Dec 25:S0360-3016(23)08259-7. doi: 10.1016/j.ijrobp.2023.12.022. Online ahead of print.
Int J Radiat Oncol Biol Phys. 2023.
PMID: 38151191
Analysis of Patient-Reported Outcome Utilization Within National Clinical Trials Network Cooperative Group Radiation Oncology Trials Over the Past 2 Decades.
Howell JN, Anker CJ, Walker AJ, Dorth JA, Kharofa JR.
Howell JN, et al.
Int J Radiat Oncol Biol Phys. 2021 Apr 1;109(5):1151-1160. doi: 10.1016/j.ijrobp.2020.12.007. Epub 2020 Dec 13.
Int J Radiat Oncol Biol Phys. 2021.
PMID: 33321191
Review.
Brain and head and neck trials demonstrated the largest proportional incorporation of PROs (81.8% and 76.9%, respectively), and thoracic and breast trials used the fewest (18.8% and 37.5%, respectively). The EQ-5D family of questionnaires was the most commonly used PROs, u …
Brain and head and neck trials demonstrated the largest proportional incorporation of PROs (81.8% and 76.9%, respectively), and thoracic and …
Item in Clipboard
Quality of Life in Patients With Chronic Limb-Threatening Ischemia Treated With Revascularization.
Menard MT, Farber A, Powell RJ, Rosenfield K, Conte MS, Hamza TH, Kaufman JA, Cziraky MJ, Creager MA, Dake MD, Jaff MR, Reid D, Sopko G, White CJ, Strong MB, van Over M, Chisci E, Goodney PP, Gray B, Kayssi A, Siracuse JJ, Choudhry NK; BEST-CLI Investigators.
Menard MT, et al.
Circulation. 2024 Apr 16;149(16):1241-1253. doi: 10.1161/CIRCULATIONAHA.123.065277. Epub 2024 Apr 10.
Circulation. 2024.
PMID: 38597097
Free article.
Clinical Trial.
HRQoL was assessed over the trial duration using Vascular Quality-of-Life (VascuQoL), European Quality-of-Life-5D (EQ-5D), the Short Form-12 (SF-12) Physical Component Summary (SF-12 PCS), SF-12 Mental Component Summary (SF-12 MCS), Utility Index Score (SF-6D R2), a …
HRQoL was assessed over the trial duration using Vascular Quality-of-Life (VascuQoL), European Quality-of-Life-5D (EQ-5D), the …
Item in Clipboard
Quality of life outcomes with BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: the DEFINE study.
Kappos L, Gold R, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, Sarda SP, Agarwal S, Zhang A, Sheikh SI, Seidman E, Dawson KT.
Kappos L, et al.
Mult Scler. 2014 Feb;20(2):243-52. doi: 10.1177/1352458513507817. Epub 2013 Oct 22.
Mult Scler. 2014.
PMID: 24150779
Clinical Trial.
HRQoL was assessed by the Short Form-36 (SF-36), global assessment of well-being visual analog scale and the EuroQol-5D. RESULTS: In the 1237 patients from DEFINE, HRQoL impairment was greatest in patients who had higher disability scores and in those who had experienced r …
HRQoL was assessed by the Short Form-36 (SF-36), global assessment of well-being visual analog scale and the EuroQol-5D. RESULTS: In …
Item in Clipboard
Cite
Cite